Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

BACKGROUND: Acute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Völkel, Sara, Tarawneh, Thomas S., Sacher, Laura, Bhagwat, Aditya M., Karim, Ihab, Mack, Hildegard I. D., Wiesmann, Thomas, Beutel, Björn, Hoyer, Joachim, Keller, Christian, Renz, Harald, Burchert, Andreas, Neubauer, Andreas, Graumann, Johannes, Skevaki, Chrysanthi, Mack, Elisabeth K. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244732/
https://www.ncbi.nlm.nih.gov/pubmed/37293294
http://dx.doi.org/10.3389/fmed.2023.1176427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244732/
https://www.ncbi.nlm.nih.gov/pubmed/37293294
http://dx.doi.org/10.3389/fmed.2023.1176427

Ejemplares similares